SCSCYNEXIS, Inc. SCYX · NASDAQ
$3.66 -0.27% (-$0.01)
- Market cap
- $23.0M
- Enterprise value
- $14.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 1.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -32.4%
- Gross margin
- 100.0%
- Net margin
- -53.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.06
- Free float
- 96.5%
About the company
SCYNEXIS, Inc. (SCYX) is a biotechnology company specializing in research, development, and commercialization of novel drugs for the treatment of infectious diseases. The company focuses on the discovery and development of innovative drugs targeting various types of infectious diseases, including fungal infections and resistant bacteria. SCYNEXIS aims to develop drugs that are effective and safe for patients with infectious diseases and can bring improvements in the treatment of these conditions. The company also conducts clinical trials and collaborates with medical institutions and pharmaceutical companies to further develop and commercialize its drugs. SCYNEXIS, Inc. (SCYX) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company with a focus on developing new drugs for the treatment of infectious diseases.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
David Angulo
Employees
18
Headquarters
Jersey City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number